Davide Capodanno, Catania, Italy, Gilles Montalescot, Paris, France, and Dominik Angiolillo, Jacksonville, USA discuss how to manage antithrombotic therapy in patients with COVID-19 undergoing interventional procedures.
Key take-home messages:
– COVID-19 disease is a prothrombotic state
– when using antiplatelets, be well aware of drug to drug interaction
– most COVID-19 patients will require anticoagulants and LWMH is the preferred drug
– when asymptomatic, COVID-19 patients should not be switched between anticoagulants
More resources on COVID-19 for interventional cardiovascular medicine: